Burrows Scott L
SEC CIK 1853327 · EDGAR
BoughtSold
Most active insiders at SYRE, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Fairmount Funds Management LLC | Dir | — | $399.66M |
| 2 | Turtle Cameron | CEO, Dir | — | $9.99M |
| 3 | HENDERSON MICHAEL THOMAS | Dir | — | $7.95M |
| 4 | Sloan Sheldon | Chief Medical Off | — | $7.35M |
| 5 | Burrows Scott L | CFO | — | $6.86M |
| 6 | King-Jones Heidy | See Remarks | — | $2.48M |
| 7 | Albers Jeffrey W. | Dir | — | $2.40M |
Transactions 27
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-09-03 21:33 | 2026-09-01 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | CFO | M - OptEx | $14.50 | +7,500 | 105.5K | +8% | +$108.8K |
| DMT | 2026-09-03 21:33 | 2026-09-01+ | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | CFO | S - Sale+OE | $88.75 | -25.7K | 79.8K | -24% | -$2.28M |
| DT | 2026-08-05 21:32 | 2026-08-03 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | CFO | M - OptEx | $14.50 | +7,500 | 105.5K | +8% | +$108.8K |
| DMT | 2026-08-05 21:32 | 2026-08-03 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | CFO | S - Sale+OE | $95.57 | -7,500 | 98.0K | -7% | -$716.8K |
| DT | 2026-07-02 21:33 | 2026-07-01 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | CFO | M - OptEx | $14.50 | +7,500 | 105.5K | +8% | +$108.8K |
| DMT | 2026-07-02 21:33 | 2026-07-01 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | CFO | S - Sale+OE | $87.74 | -7,500 | 98.0K | -7% | -$658.0K |
| D | 2026-06-26 21:31 | 2026-06-25 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | CFO | M - OptEx | $14.50 | +15.0K | 113.0K | +15% | +$217.5K |
| DM | 2026-06-26 21:31 | 2026-06-25 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | CFO | S - Sale+OE | $87.13 | -15.0K | 98.0K | -13% | -$1.31M |
| DT | 2026-06-03 21:30 | 2026-06-01 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | CFO | M - OptEx | $14.50 | +7,500 | 105.5K | +8% | +$108.8K |
| DMT | 2026-06-03 21:30 | 2026-06-01 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | CFO | S - Sale+OE | $71.06 | -7,500 | 98.0K | -7% | -$532.9K |
| DT | 2026-05-01 21:35 | 2026-05-01 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | CFO | M - OptEx | $14.50 | +12.5K | 110.5K | +13% | +$181.2K |
| DT | 2026-05-01 21:35 | 2026-05-01 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | CFO | S - Sale+OE | $71.37 | -12.5K | 98.0K | -11% | -$892.1K |
| DT | 2026-04-03 21:29 | 2026-04-01 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | CFO | M - OptEx | $14.50 | +7,500 | 105.5K | +8% | +$108.8K |
| DMT | 2026-04-03 21:29 | 2026-04-01 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | CFO | S - Sale+OE | $49.34 | -7,500 | 98.0K | -7% | -$370.1K |
| DM | 2026-03-03 | 2026-03-03 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | CFO | S - Sale+OE | $40.65 | -2,500 | 98.2K | -2% | -$101.6K |
| D | 2026-03-03 | 2026-03-03 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | CFO | M - OptEx | $14.50 | +2,500 | 100.5K | +3% | +$36.2K |
| 2025-09-03 | 2025-09-02 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | CFO | S - Sale | $16.26 | -18.4K | 98.0K | -16% | -$299.6K | |
| 2024-09-05 | 2024-09-03 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | CFO | S - Sale | $28.17 | -18.5K | 116.4K | -14% | -$522.0K | |
| 2023-12-22 | 2023-12-22 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | CFO | A - Grant | $0.00 | +135.0K | 135.0K | New | $0 | |
| 2023-03-08 | 2023-03-06 | ARQT | Arcutis Biotherapeutics, Inc. | Burrows Scott L | CFO | S - Sale | $15.26 | -291 | 59.1K | -0.5% | -$4,441 | |
| D | 2023-03-06 | 2023-03-02 | ARQT | Arcutis Biotherapeutics, Inc. | Burrows Scott L | CFO | A - Grant | $0.00 | +21.0K | 59.4K | +55% | $0 |
| M | 2023-03-02 | 2023-02-28+ | ARQT | Arcutis Biotherapeutics, Inc. | Burrows Scott L | CFO | S - Sale | $15.91 | -1,850 | 39.8K | -4% | -$29.4K |
| D | 2022-09-20 | 2022-09-16 | ARQT | Arcutis Biotherapeutics, Inc. | Burrows Scott L | CFO | M - OptEx | $1.68 | +5,000 | 40.3K | +14% | +$8,400 |
| D | 2022-03-07 | 2022-03-03 | ARQT | Arcutis Biotherapeutics, Inc. | Burrows Scott L | CFO | A - Grant | $0.00 | +13.3K | 35.6K | +60% | $0 |
| DM | 2022-03-07 | 2022-03-04+ | ARQT | Arcutis Biotherapeutics, Inc. | Burrows Scott L | CFO | S - Sale | $16.85 | -303 | 35.3K | -0.9% | -$5,104 |
| 2022-03-03 | 2022-03-01 | ARQT | Arcutis Biotherapeutics, Inc. | Burrows Scott L | CFO | S - Sale | $17.75 | -420 | 22.3K | -2% | -$7,455 | |
| 2021-12-28 | 2021-12-27 | ARQT | Arcutis Biotherapeutics, Inc. | Burrows Scott L | CFO | S - Sale | $20.07 | -12.6K | 22.7K | -36% | -$252.1K |
Purchase Sale Sale after option exercise All abbreviations